Technical Analysis for ATNRW - Actinium Pharmaceuticals Inc Series A [03/02/201

Grade Last Price % Change Price Change
grade F 0.01 0.00% 0.0000
ATNRW closed unchanged on Friday, March 1, 2019, on 2.24 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical ATNRW trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -60.00%
Narrow Range Bar Range Contraction -60.00%

Older signals for ATNRW ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Medicine RTT Medical Specialties Clinical Medicine Biopharmaceutical Cancers Leukemia Multiple Myeloma Acute Myeloid Leukemia Hematopoietic Stem Cell Transplantation Bone Marrow Transplant Actimab Camidanlumab Tesirine Cd135 Refractory Acute Myeloid Leukemia Refractory Multiple Myeloma Therapies For Patients With Cancers
Is ATNRW a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.37
52 Week Low 0.01
Average Volume 27,858
200-Day Moving Average 0.0
50-Day Moving Average 0.1755
20-Day Moving Average 0.0718
10-Day Moving Average 0.037
Average True Range 0.0296
ADX 31.58
+DI 27.2617
-DI 48.21
Chandelier Exit (Long, 3 ATRs ) 0.1212
Chandelier Exit (Short, 3 ATRs ) 0.0988
Upper Bollinger Band 0.1842
Lower Bollinger Band -0.0406
Percent B (%b) 0.23
BandWidth 313.091922
MACD Line -0.0461
MACD Signal Line -0.0456
MACD Histogram -0.0005
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0100
Resistance 3 (R3) 0.0100 0.0100 0.0100
Resistance 2 (R2) 0.0100 0.0100 0.0100 0.0100
Resistance 1 (R1) 0.0100 0.0100 0.0100 0.0100 0.0100
Pivot Point 0.0100 0.0100 0.0100 0.0100 0.0100
Support 1 (S1) 0.0100 0.0100 0.0100 0.0100 0.0100
Support 2 (S2) 0.0100 0.0100 0.0100 0.0100
Support 3 (S3) 0.0100 0.0100 0.0100
Support 4 (S4) 0.0100